Summary

Overview
The global anticoagulation therapy market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Anticoagulants, also known as blood thinners, are chemical substances that prevent or reduce blood coagulation, thereby extending clotting time.
Anticoagulation or clot prevention can be directed at different sites of the coagulation pathway, with overlaps at multiple points. Direct thrombin inhibitors and direct factor 10a inhibitors can inhibit the formation of a fibrin clot. Other mechanisms through which anticoagulation can be achieved include inhibition of vitamin K-dependent factors by preventing their synthesis in the liver or modification of their calcium-binding properties.
The role of anticoagulation therapy (ACT) in childhood CSVT is supported by adult clinical trials pediatric cohort studies and ACT experience in systemic thrombosis. The goal of ACT is to maintain sinovenous system patency by preventing thrombus propagation and new thrombosis. The exact frequency with which children are anticoagulated is unknown as practice patterns vary even among pediatric stroke experts. Factors influencing treatment decisions include the child's age, thrombus extent/location, CSVT propagation, ICH, reversibility of associated risk factors, and capacity to monitor ACT.
Market Dynamics: Drivers
Growing Demand for Anticoagulation Drugs
The demand for the anticoagulation therapy market is driven by multiple factors. An anticoagulant is a medication (blood thinner) that treats, prevents, and lowers the risk of blood clots breaking off and traveling to vital organs in the body, resulting in life-threatening situations.
They work by preventing blood from clotting in vital organs such as the heart, lungs, and brain. Anticoagulant therapy is used to prevent the formation of new blood clots and treat existing clots by preventing them from growing in size. It also reduces the risk of blood clot embolization in other vital organs such as the lungs and brain.
Anticoagulant sales are expected to increase significantly in developed countries due to increased financial support provided by government authorities to strengthen healthcare infrastructure in the public interest. Anticoagulant drug innovations are being driven by applications of anticoagulants for blood clotting prevention.
These efforts are intended to improve efficacy by encouraging leading market players to invest heavily in R&D for better product portfolios. The cost-effectiveness of traditional anticoagulants such as Warfarin is driving sales in emerging markets. However, the current dominance impedes demand for advanced anticoagulant drugs in some countries. Long-term treatments and a large budget allocation for advanced anticoagulants also influence growth.
In addition, technological advantages and innovations in drug discovery drive this market. As per ACS publication in April 2023, Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be an effective and safe target for anticoagulant discovery with limited or no bleeding. Numerous small-molecule FXIa inhibitors (SMFIs) with various scaffolds have been identified in the early stages of drug discovery.
For instance, in February 2022, The FDA approved fast-track designation to Bayer's investigational medication asundexian (BAY2433334), which may be used to treat patients who have had a non-cardioembolic ischemic stroke as a secondary preventive measure.
Restraints
Factors such as side effects associated with the drugs, drug-drug interaction, high development expenditure with stringent regulations, lack of awareness, and high cost of the therapy are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The anticoagulation therapy market is segmented based on drug class, application, and region.
The novel oral anticoagulants (NOACs) segment accounted for approximately 48.5% of the anticoagulation therapy market share
The novel oral anticoagulants (NOACs) segment is expected to hold the largest market share over the forecast period owing to the increasing adoption of NOACs in developing countries and the high preference for NOACs over warfarin.
NOACs (novel oral anticoagulants) are a new class of anticoagulant medications. Furthermore, they are safe (lower incidence of major bleeding), easy to use, have no food interactions, and have a shorter half-life. Dabigatran, rivaroxaban, apixaban, and edoxaban are among the NOACs. These medications can be used to prevent and treat atrial fibrillation/myocardial infarction, deep vein thrombosis (DVT), and pulmonary embolism.
Apixaban, dabigatran, rivaroxaban, and edoxaban are examples of novel oral anticoagulants (NOACs). NOACs are warfarin alternatives for high-risk patients with atrial fibrillation (including those with a history of stroke).
Dabigatran is a direct thrombin inhibitor, whereas apixaban, edoxaban, and rivaroxaban inhibit Factor Xa. Apixaban and dabigatran were found to be more effective than warfarin in preventing stroke and systemic embolism, while rivaroxaban and edoxaban were found to be equivalent. When compared to warfarin, NOACs have a lower rate of intracranial hemorrhage. Apixaban is the last NOAC approved by the FDA and EMA to prevent stroke and embolism in non-valvular AF. It is a direct, reversible, competitive, and selective factor Xa inhibitor.
As per CDC estimates in June 2022, in the U.S. approximately 9,00,000 individuals were affected by deep vein thrombosis, in addition, around 1,00,000 people died due to the thrombosis.
Furthermore, key players in the industry launched products and approvals people the market growth in this region. For instance, in June 2022, The US Food and Drug Administration (FDA) approved Pradaxa (dabigatran etexilate) oral pellets from Boehringer Ingelheim Pharmaceuticals for pediatric patients aged three months to 12 years with venous thromboembolism.
Also, in June 2021, Pradaxa became the first FDA-approved blood-thinning medication for children that can be taken orally. It is intended for stroke and blood clot prevention in patients with irregular heart rhythms (atrial fibrillation).
Geographical Analysis
North America accounted for approximately 41.2% of the anticoagulation therapy market share
North America region is expected to hold the largest market share over the forecast period. The increasing incidence of cardiovascular diseases is expected to drive market growth in this region. For instance, according to the Centers for Disease Control and Prevention (CDC), in March 2024, approximately 900,000 people ((1 to 2 per 1,000 population)) in the United States are at risk of developing deep vein thrombosis each year.
Furthermore, deep vein thrombosis kills between 60,000 and 100,000 Americans each year. According to the American Heart Association, approximately 2,300 Americans die each day due to cardiovascular diseases, an average of one death every 38 seconds. Furthermore, the presence of top pharma and biotech companies involved in therapeutic development and well-established healthcare infrastructure is fueling the overall regional market's growth to a large extent.
Moreover, in this region, well-developed healthcare infrastructure, the presence of a major number of key players, and new product approvals would drive the market. For instance, in December 2021, the U.S. FDA approved XARELTO (rivaroxaban) has two new indications to help treat and prevent blood clots in pediatric patients.
Convenient oral suspension formulation advances the standard of care for children; and alleviates administration challenges found with injectable alternatives. XARELTO now has 11 indications, the most of any direct oral anticoagulant (DOAC), and is the only Factor Xa anticoagulant to offer flexible weight-based dosing for pediatric patients.
Also, in March 2021, The US National Institutes of Health (NIH) initiated the last of three Phase III clinical trials of blood thinners (anticoagulants) to prevent life-threatening blood clots in adults with COVID-19.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the anticoagulation therapy market. Thrombotic complications (both arterial and venous) are common in COVID-19 patients admitted to hospitals and are an independent predictor of poor outcomes.
Microvascular thrombi can also cause organ dysfunction, such as acute respiratory distress syndrome. The pathogenesis of thrombosis in COVID-19 is intimately related to the virus's inflammatory response, endothelial infection, activation, and injury, as well as hypercoagulability. Recognizing that thrombosis is a significant cause of clinical deterioration and death has piqued global interest in whether increasing anticoagulation dose or duration improves patient outcomes.
Unless the risk of bleeding even on prophylactic dosing outweighs the risk of thrombosis, all hospitalized adults with COVID-19 should receive pharmacologic thromboprophylaxis. Unfractionated heparin is preferred over LMWH (UFH). Fondaparinux is recommended in the treatment of heparin-induced thrombocytopenia.
Market Segmentation
By Drug Class
- Novel Oral Anticoagulants (NOACs)
- Apixaban
- Dabigatran
- Rivaroxaban
- Edoxaban
- Heparin and Low Molecular Weight Heparin (LMWH)
- Lovenox
- Fragmin
- Innohep
- Vitamin K Antagonist
By Application
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the anticoagulation therapy market include Boehringer Ingelheim GmbH, Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, GlaxoSmithKline Plc, Aspen Holdings, Pfizer, Inc Alexion Pharmaceuticals, Inc., Bristol-Myers Squibb Co., Sanofi-Aventis U.S. LLC among others.
Key Developments
- On March 29, 2024, AstraZeneca AB announced U.S. FDA approved Andexxa coagulation factor Xa (recombinant), inactivated-zhzo. It was stated for patients acquiring rivaroxaban and apixaban medication if anticoagulation medication is required prevented due to acute or excessive bleeding.
- On February 12, 2024, Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient needs. These novel analyses could assist surgeons create smarter choices regarding prescribing the use of immediate intravenous anticoagulants while attempting to prevent seizures.
- On December 5, 2023, Sirnaomics Ltd. together with its subsidiaries, announced the successful completion of Cohort 1 in an ongoing Phase I clinical trial of STP122G, targeting Factor XI as a novel form of anticoagulation.
- On November 6, 2023, Bayer expanded its Phase III OCEANIC clinical development program for the investigational drug asundexian (BAY2433334) by initiating a third clinical study, OCEANIC-AFINA. Asundexian is currently being researched to be an alternative therapy in the Phase III OCEANIC AFINA investigation for individuals (?65 years old) with irregular heartbeats (AF) that have a significant risk for ischemic stroke or pulmonary embolism and are therefore unable for oral coagulation inhibitor (OAC) drugs due to a greater chance of blood loss.
Why Purchase the Report?
- To visualize the anticoagulation therapy market segmentation based on drug class, application, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of anticoagulation therapy market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in excel consisting of key products of all the major players.
The anticoagulation therapy market report would provide approximately 36 tables, 29 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Application
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Anticoagulation Drugs
4.1.2. Restraints
4.1.2.1. Side Effects Associated with the Medication
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Novel Oral Anticoagulants (NOACs)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Apixaban
7.4. Dabigatran
7.5. Rivaroxaban
7.6. Edoxaban
7.7. Heparin and Low Molecular Weight Heparin (LMWH)
7.8. Lovenox
7.9. Fragmin
7.10. Innohep
7.11. Vitamin K Antagonist
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Atrial Fibrillation/Myocardial Infarction (Heart Attack) *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Deep Vein Thrombosis (DVT)
8.4. Pulmonary Embolism
8.5. Others
8.6. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. South Korea
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Boehringer Ingelheim GmbH *
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Johnson & Johnson
11.3. Bayer AG
11.4. Pfizer, Inc
11.5. Daiichi Sankyo Company
11.6. GlaxoSmithKline Plc
11.7. Aspen Holdings
11.8. Alexion Pharmaceuticals, Inc.
11.9. Bristol-Myers Squibb Co.
11.10. Sanofi-Aventis U.S. LLC
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us